Original ArticleElectronic Pancreas, Biliary Tract, and LiverCachexia is Prevalent in Patients With Hepatocellular Carcinoma and Associated With Worse Prognosis
Section snippets
Study Cohort
We identified consecutive patients diagnosed with HCC between January 2008 and December 2018 at 2 large United States health systems, the University of Texas Southwestern Medical Center and Parkland Health and Hospital System, using our prospectively maintained institutional database. All HCC diagnoses were confirmed on chart review using the American Association for the Study of Liver Diseases guidelines (ie, characteristic imaging findings [Liver Imaging Reporting and Data System] or
Patient Characteristics
Clinical characteristics of the 604 patients at time of HCC diagnosis are summarized in Table 1. The median age was 60.9 years, 72.2% were male, and over one-half (56.2%) had Child Pugh class A cirrhosis. The cohort was diverse with regard to race and ethnicity (32.1% white, 34.1% black, and 29.0% Hispanic) and tumor stage (58.6% BCLC stage A, 16.3% B, 16.8% C, and 8.3% stage D).
Prevalence and Correlates of Cachexia
At the time of HCC diagnosis, 143 patients (23.7%) had cachexia, including 19.0%, 23.5%, 34.7%, and 34.0% of patients
Discussion
Although cachexia has been identified as an important prognostic factor in several cancers, data are limited on its prevalence and clinical significance in HCC. In this study using clinically granular data from a large and diverse cohort, we found that pretreatment weight loss is prevalent, with 25% of patients experiencing cachexia and 33% of patients having precachexia. Cachexia and precachexia impacted patients across the spectrum of cirrhosis severity and HCC tumor stages, including some
Conclusions
In conclusion, we found 1 in 4 patients with HCC present with cachexia, which appears to be an important prognostic factor in HCC. Given its association with survival, early recognition and treatment of cancer-associated wasting is a potential novel intervention target for reducing mortality in patients with HCC.
CRediT Authorship Contributions
Nicole E. Rich (Conceptualization: Equal; Data curation: Lead; Formal analysis: Equal; Methodology: Equal; Visualization: Lead; Writing – original draft: Lead; Writing – review & editing: Equal)
Samuel Phen (Data curation: Equal; Writing – review & editing: Supporting; data abstraction: Equal)
Nirali Desai (Data curation: Equal; Writing – review & editing: Supporting; data abstraction: Equal)
Sukul Mittal (Data curation: Equal; Writing – review & editing: Supporting; data abstraction: Supporting)
References (42)
- et al.
Contemporary epidemiology of chronic liver disease and cirrhosis
Clin Gastroenterol Hepatol
(2020) - et al.
Hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease
Clin Gastroenterol Hepatol
(2016) - et al.
Frailty associated with waitlist mortality independent of ascites and hepatic encephalopathy in a multicenter study
Gastroenterology
(2019) - et al.
Physical frailty after liver transplantation
Am J Transplant
(2018) - et al.
Definition and classification of cancer cachexia: an international consensus
Lancet Oncol
(2011) - et al.
Cachexia worsens prognosis in patients with resectable pancreatic cancer
J Gastrointest Surg
(2008) - et al.
Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma
Clin Gastroenterol Hepatol
(2019) - et al.
ESPEN guideline on clinical nutrition in liver disease
Clin Nutr
(2019) - et al.
Sarcopenia and frailty in decompensated cirrhosis
J Hepatol
(2021) - et al.
Correlation between the international consensus definition of the Cancer Anorexia-Cachexia Syndrome (CACS) and patient-centered outcomes in advanced non-small cell lung cancer
J Pain Symptom Manage
(2015)
Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies
J Hepatol
Cachexia: a preventable comorbidity of cancer. A T.A.R.G.E.T. approach
Crit Rev Oncol Hematol
Sarcopenia as a predictor of prognosis in patients following hepatectomy for hepatocellular carcinoma
Br J Surg
Performance status in patients with hepatocellular carcinoma: determinants, prognostic impact, and ability to improve the Barcelona Clinic Liver Cancer system
Hepatology
Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma
J Clin Gastroenterol
Development of a novel frailty index to predict mortality in patients with end-stage liver disease
Hepatology
Cachexia-associated adipose loss induced by tumor-secreted leukemia inhibitory factor is counterbalanced by decreased leptin
JCI Insight
Mechanisms of cancer cachexia
Physiol Rev
Cancer cachexia, mechanism and treatment
World J Gastrointest Oncol
Janus kinase inhibitors suppress cancer cachexia-associated anorexia and adipose wasting in mice
JCSM Rapid Commun
Impact of socioeconomic status on pretreatment weight loss and survival in non–small-cell lung cancer
J Oncol Pract
Cited by (12)
Inpatient Outcomes of Cirrhosis-related Cachexia in the United States
2024, Gastro Hep AdvancesReply
2022, Clinical Gastroenterology and HepatologyLook for a Physical Health Status Surrogate in Hepatocellular Carcinoma: Have we Found the Holy Grail?
2022, Clinical Gastroenterology and HepatologyClinical significance of cachexia index in patients with hepatocellular carcinoma after hepatic resection
2022, Surgical OncologyCitation Excerpt :Cachexia is a wasting syndrome seen in cancers and many chronic diseases. A recent study has shown that cancer cachexia is an adverse prognostic factor of patients with malignancies including HCC [7]. Cancer cachexia is a multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment [8].
Body Composition in Chronic Liver Disease
2024, International Journal of Molecular Sciences
Conflicts of interest These authors disclose the following: Nicole Rich serves as a consultant for AstraZeneca. Jorge Marrero has served as a consultant for Glycotest and received research funding from AstraZeneca. Amit Singal has been on advisory boards and served as a consultant for Wako Diagnostics, Roche, Exact Sciences, Glycotest, GRAIL, Bayer, Eisai, Exelixis, BMS, AstraZeneca, Genentech, and TARGET-RWE. Pfizer, Inc. is currently supporting a collaborative project with the laboratory of Rodney Infante that is independent of all data presented in this manuscript. The remaining authors disclose no conflicts.
Funding Amit G. Singal is supported by National Institutes of Health grants R01 CA222900 and R01 MD12565. Jorge A. Marrero is supported by National Institutes of Health grant R01 CA237659. Rodney E. Infante is supported by Burroughs Wellcome Fund Career Awards for Medical Scientists (1019692); American Gastroenterological Association Scholar Award (2019AGARSA3); American Cancer Society grant (133889-RSG-19-195-01-TBE); Cancer Prevention and Research Institute of Texas (RP200170); and the V Foundation Scholar Award (V2019-014). Nicole E. Rich is supported by the American College of Gastroenterology Junior Faculty Development Award and the Texas Health Resources Clinical Scholar Award. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
- a
Authors share co-senior authorship.